Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis

NeuroReport

Volumn 16, Issue 6, 2005, Pages 527-531

  Weydt, Patrick ^a   Möller, Thomas ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Microglia; Motor neuron; Neuroinflammation; Noncell autonomous

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 6; MINOCYCLINE; TETRACYCLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MICROGLIA; MOTOR NEURON DISEASE; NERVE INJURY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ENCEPHALITIS; HUMANS; MICROGLIA; MOTOR NEURONS;

EID: 17844395669     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200504250-00001     Document Type: Review

References (38)

1. Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 2003; 98:379-414.
2. Brujin LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27:723-749.
3. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344:1688-1700.
4. Brown RH, Meininger V, Swash M (eds). Amyotrophic Lateral Sclerosis. London: Martin Dunitz; 2000.
5. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
6. Subramaniam JR, Lyons WE, Liu J, Bartnikas TB, Rothstein J, Price DL et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002; 5:301-307.
7. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2:806-819.
8. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85-92.
9. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002; 40:133-139.
10. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19:312-318.
11. Hanisch UK. Microglia as a source and target of cytokines. Glia 2002; 40:140-155.
12. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002; 35:419-432.
13. McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 1999; 5:821-836.
14. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23:249-256.
15. Weydt P, Weiss MD, Moller T, Carter GT. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs 2002; 3:1720-1724.
16. Weydt P, Yuen EC, Ransom BR, Moller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004; 48:179-182.
17. Ince PG, Shaw PJ, Slade JY, Jones C, Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol (Berl) 1996; 92:395-403.
18. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15:601-609.
19. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2005; 159:215-224.
20. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 2002; 32:360-371.
21. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001; 57:1282-1289.
22. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 2000; 20:660-665.
23. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001; 21:3369-3374.
24. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113-117.
25. Cleveland DW. Presidential symposium: from Charcot to Lou Gehrig: motor neuron growth and death. 34th Annual Meeting of the Society for Neuroscience, San Diego, USA. October, 2004.
26. Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2001; 95:172-178.
27. Xie Y, Weydt P, Howland DS, Kliot M, Moller T. Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport 2004; 15:2513-2516.
28. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992; 140:691-707.
29. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36: 180-190.
30. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci 2004; 25:609-612.
31. Kriz J, Nguyen M, Julien J. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10:268.
32. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417:74-78.
33. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13:1067-1070.
34. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004; 62:1845-1847.
35. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2:879-890.
36. Maihofner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundorfer B, Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003; 18:1527-1534.
37. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS - a dual role? Exp Neurol 2004; 187:1-10.
38. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002; 52:771-778.